Search: onr:"swepub:oai:DiVA.org:umu-165382" > EAU–ESMO consensus ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08020naa a2201837 4500 | |
001 | oai:DiVA.org:umu-165382 | |
003 | SwePub | |
008 | 191122s2019 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:142774126 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1653822 URI |
024 | 7 | a https://doi.org/10.1093/annonc/mdz2962 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1427741262 URI |
040 | a (SwePub)umud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Horwich, A4 aut |
245 | 1 0 | a EAU–ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multi-stakeholder effort :b under the auspices of the EAU and ESMO Guidelines Committees |
264 | 1 | b Oxford University Press,c 2019 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.SETTING: Online Delphi survey and consensus conference.PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng |
653 | a Delphi | |
653 | a bladder cancer | |
653 | a consensus | |
653 | a diagnosis | |
653 | a follow-up | |
653 | a treatment | |
700 | 1 | a Babjuk, M4 aut |
700 | 1 | a Bellmunt, J4 aut |
700 | 1 | a Bruins, H M4 aut |
700 | 1 | a Reijke, T M De4 aut |
700 | 1 | a Santis, M De4 aut |
700 | 1 | a Gillessen, S4 aut |
700 | 1 | a James, N4 aut |
700 | 1 | a Maclennan, S4 aut |
700 | 1 | a Palou, J4 aut |
700 | 1 | a Powles, T4 aut |
700 | 1 | a Ribal, M J4 aut |
700 | 1 | a Shariat, S F4 aut |
700 | 1 | a Kwast, T Van Der4 aut |
700 | 1 | a Xylinas, E4 aut |
700 | 1 | a Agarwal, N4 aut |
700 | 1 | a Arends, T4 aut |
700 | 1 | a Bamias, A4 aut |
700 | 1 | a Birtle, A4 aut |
700 | 1 | a Black, P C4 aut |
700 | 1 | a Bochner, B H4 aut |
700 | 1 | a Bolla, M4 aut |
700 | 1 | a Boormans, J L4 aut |
700 | 1 | a Bossi, A4 aut |
700 | 1 | a Briganti, A4 aut |
700 | 1 | a Brummelhuis, I4 aut |
700 | 1 | a Burger, M4 aut |
700 | 1 | a Castellano, D4 aut |
700 | 1 | a Cathomas, R4 aut |
700 | 1 | a Chiti, A4 aut |
700 | 1 | a Choudhury, A4 aut |
700 | 1 | a Compérat, E4 aut |
700 | 1 | a Crabb, S4 aut |
700 | 1 | a Culine, S4 aut |
700 | 1 | a Bari, B De4 aut |
700 | 1 | a Blok, W De4 aut |
700 | 1 | a De Visschere, P J L4 aut |
700 | 1 | a Decaestecker, K4 aut |
700 | 1 | a Dimitropoulos, K4 aut |
700 | 1 | a Dominguez-Escrig, J L4 aut |
700 | 1 | a Fanti, S4 aut |
700 | 1 | a Fonteyne, V4 aut |
700 | 1 | a Frydenberg, M4 aut |
700 | 1 | a Futterer, J J4 aut |
700 | 1 | a Gakis, G4 aut |
700 | 1 | a Geavlete, B4 aut |
700 | 1 | a Gontero, P4 aut |
700 | 1 | a Grubmüller, B4 aut |
700 | 1 | a Hafeez, S4 aut |
700 | 1 | a Hansel, D E4 aut |
700 | 1 | a Hartmann, A4 aut |
700 | 1 | a Hayne, D4 aut |
700 | 1 | a Henry, A M4 aut |
700 | 1 | a Hernandez, V4 aut |
700 | 1 | a Herr, H4 aut |
700 | 1 | a Herrmann, K4 aut |
700 | 1 | a Hoskin, P4 aut |
700 | 1 | a Huguet, J4 aut |
700 | 1 | a Jereczek-Fossa, B A4 aut |
700 | 1 | a Jones, R4 aut |
700 | 1 | a Kamat, A M4 aut |
700 | 1 | a Khoo, V4 aut |
700 | 1 | a Kiltie, A E4 aut |
700 | 1 | a Krege, S4 aut |
700 | 1 | a Ladoire, S4 aut |
700 | 1 | a Lara, P C4 aut |
700 | 1 | a Leliveld, A4 aut |
700 | 1 | a Linares-Espinós, E4 aut |
700 | 1 | a Løgager, V4 aut |
700 | 1 | a Lorch, A4 aut |
700 | 1 | a Loriot, Y4 aut |
700 | 1 | a Meijer, R4 aut |
700 | 1 | a Mir, M Carmen4 aut |
700 | 1 | a Moschini, M4 aut |
700 | 1 | a Mostafid, H4 aut |
700 | 1 | a Müller, A-C4 aut |
700 | 1 | a Müller, C R4 aut |
700 | 1 | a N'Dow, J4 aut |
700 | 1 | a Necchi, A4 aut |
700 | 1 | a Neuzillet, Y4 aut |
700 | 1 | a Oddens, J R4 aut |
700 | 1 | a Oldenburg, J4 aut |
700 | 1 | a Osanto, S4 aut |
700 | 1 | a Oyen, W J G4 aut |
700 | 1 | a Pacheco-Figueiredo, L4 aut |
700 | 1 | a Pappot, H4 aut |
700 | 1 | a Patel, M I4 aut |
700 | 1 | a Pieters, B R4 aut |
700 | 1 | a Plass, K4 aut |
700 | 1 | a Remzi, M4 aut |
700 | 1 | a Retz, M4 aut |
700 | 1 | a Richenberg, J4 aut |
700 | 1 | a Rink, M4 aut |
700 | 1 | a Roghmann, F4 aut |
700 | 1 | a Rosenberg, J E4 aut |
700 | 1 | a Rouprêt, M4 aut |
700 | 1 | a Rouvière, O4 aut |
700 | 1 | a Salembier, C4 aut |
700 | 1 | a Salminen, A4 aut |
700 | 1 | a Sargos, P4 aut |
700 | 1 | a Sengupta, S4 aut |
700 | 1 | a Sherif, Amiru Umeå universitet,Urologi och andrologi4 aut0 (Swepub:umu)amsh0008 |
700 | 1 | a Smeenk, R J4 aut |
700 | 1 | a Smits, A4 aut |
700 | 1 | a Stenzl, A4 aut |
700 | 1 | a Thalmann, G N4 aut |
700 | 1 | a Tombal, B4 aut |
700 | 1 | a Turkbey, B4 aut |
700 | 1 | a Lauridsen, S Vahr4 aut |
700 | 1 | a Valdagni, R4 aut |
700 | 1 | a Van Der Heijden, A G4 aut |
700 | 1 | a Van Poppel, H4 aut |
700 | 1 | a Vartolomei, M D4 aut |
700 | 1 | a Veskimäe, E4 aut |
700 | 1 | a Vilaseca, A4 aut |
700 | 1 | a Rivera, F A Vives4 aut |
700 | 1 | a Wiegel, T4 aut |
700 | 1 | a Wiklund, Pu Karolinska Institutet4 aut |
700 | 1 | a Williams, A4 aut |
700 | 1 | a Zigeuner, R4 aut |
700 | 1 | a Witjes, J A4 aut |
710 | 2 | a Umeå universitetb Urologi och andrologi4 org |
773 | 0 | t Annals of Oncologyd : Oxford University Pressg 30:11, s. 1697-1727q 30:11<1697-1727x 0923-7534x 1569-8041 |
856 | 4 | u http://www.annalsofoncology.org/article/S0923753420325928/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-165382 |
856 | 4 8 | u https://doi.org/10.1093/annonc/mdz296 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:142774126 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.